Based on these results, we conclude that elevated expression of DNASE1L3 and AIM2 improve the efficacy of sorafenib in conjunction with PD-1 mAb therapy, resulting in significant tumor growth inhibition and extended survival in mice. Here, AIM2 is linked to neoplasm.